Table 2.

Characteristics of the 39 patients colonized by Pneumocystis.

Patient no.	Age (years)	Gender	Underlying condition	30-day outcome	PCR Ct value in BALF sample	Serum BG level (pg/ml)	Time between serum and BALF sampling (days)
Patients with systemic autoimmune or inflammatory disease
C1	75	F	Rheumatoid arthritis	Survived	36	57	2
C4#	71	M	Granulomatosis with polyangiitis	Survived	32.5	<31	−2
C5§	72	M	Pneumoconiosis	Survived	32.5	<31	0
C11	80	F	Systemic lupus erythematosus	Survived	36.5	76	7
C14§	54	F	Dermatomyositis	Survived	35.5	40	−1
C18	65	M	Rheumatoid arthritis	Survived	35.5	75	−1
C19	63	F	Granulomatosis with polyangiitis	Survived	37	<31	0
C21	72	M	Rheumatic fever	Died	34.5	<31	0
C31#	51	F	Multiple sclerosis	Survived	35	<31	9
Patients with solid organ transplant
C2	54	M	Kidney transplant	Survived	37	<31	14
C7	63	M	Kidney transplant	Survived	37.5	67	8
C9	67	M	Kidney transplant	Survived	35	36	14
C10	73	M	Kidney transplant	Survived	38	<31	−13
C13	78	M	Kidney transplant	Survived	36.5	<31	2
C15	48	F	Kidney transplant	Survived	38	<31	0
C16	72	F	Kidney transplant	Survived	38	34	4
C17	71	M	Kidney transplant	Survived	38	<31	−2
C20	62	F	Kidney transplant	Survived	30	<31	0
C23	68	F	Kidney transplant	Survived	31.5	44	0
C26	80	M	Kidney transplant	Died	34	51	−1
C28	62	M	Kidney transplant	Survived	34	<31	0
C29	69	F	Kidney transplant	Survived	33	<31	8
C36	77	M	Kidney transplant	Survived	32	<31	11
C37	30	M	Kidney transplant	Survived	37	<31	−5
C39	66	M	Kidney transplant	Survived	37	<31	6
Patients with hematological malignancy
C3	84	M	Follicular lymphoma	Died	36.5	54	0
C8	50	F	Acute myeloid leukemia	Survived	38	<31	15
C22	77	F	Multiple myeloma	Died	38	<31	−1
C24	63	M	Multiple myeloma	Survived	37.5	<31	14
C25	80	F	Chronic lymphocytic leukemia	Survived	36.5	69	0
C27#	38	M	Mixed-phenotype acute leukemia	Survived	35	<31	0
C30	55	F	Acute myeloid leukemia	Survived	36.5	<31	−1
C32#	54	M	Diffuse large B-cell lymphoma	Survived	37.5	<31	−9
C33	66	M	Hodgkin lymphoma	Survived	34.5	31	−1
C34	68	M	Diffuse large B-cell lymphoma	Survived	38	49	10
C35	67	M	Mantle cell lymphoma	Survived	32	57	0
Patients with solid cancer
C6	64	F	Lung adenocarcinoma	Survived	37.5	119	−3
C12	67	F	Breast cancer	Survived	35.5	66	0
C38	74	M	Lung adenocarcinoma	Survived	32	69	7

BALF, bronchoalveolar lavage fluid; BG, (1,3)-β-D-glucan; Ct, cycle threshold; F, Female; M, Male.

^#Patients with concurrent gram-negative sepsis.

^§Patients receiving methotrexate administration.